Table 1.

Clinicobiological characteristics of patients based on their ILC distribution.

	IFN-γ ELISpots hTERT patients at baseline	ILC low	ILC high	p
	n = 74 (%)	n = 50 (%)	n = 24(%)
AGE-YEARS
<65	n = 36 (49%)	22 (44%)	14 (61%)
≥65	n = 37 (51%)	28 (56%)	9 (49%)	0.28
GENDER
F	n = 27 (36%)	16 (32%)	11 (46%)
M	n = 47 (64%)	34 (68%)	13 (54%)	0.37
TUMOR LOCATION
Rectum	n = 19 (27%)	14 (30%)	5 (21%)
Colon	n = 52 (73%)	33 (70%)	19 (79%)	0.60
MICROSATELLITES
MSI	n = 8 (21%)	7 (28%)	1 (7%)
MSS	n = 31 (79%)	18 (72%)	13 (93%)	0.26
RAS STATUS
M	n = 33 (50%)	20 (45%)	13 (59%)
WT	n = 33 (50%)	24 (55%)	9 (41%)	0.43
BRAF STATUS
M	n = 8 (14%)	5 (11%)	3 (14%)
WT	n = 58 (86%)	39 (89%)	19 (86%)	0.99
TIME OF METASTASIS
Metachronous	n = 14 (20%)	12 (24%)	2 (8%)
Synchronous	n = 57 (80%)	35 (76%)	22 (92%)	0.16
METASTATIC LOCALIZATION
Extra hepatic	n = 16 (22%)	n = 14 (29%)	n = 2 (8%)
Hepatic and other	n = 19 (26%)	n = 12 (25%)	n = 7 (29%)
Hepatic only	n = 37 (52%)	n = 22 (46%)	n = 15 (63%)	0.13
METASTATIC LOCALIZATION
Extra hepatic/hepatic and other	n = 35 (49%)	n = 26 (54%)	n = 9 (37.5%)
Hepatic only	n = 37 (51%)	n = 22 (46%)	n = 15 (62.5%)	0.28
LYMPHOCYTE COUNT
<1,000	n = 9 (13%)	5 (11%)	4 (17%)
≥1,000	n = 61 (87%)	41 (89%)	20 (83%)	0.75
ACE
<20	n = 26 (43%)	19 (46%)	7 (35%)
≥20	n = 35 (57%)	22 (54%)	13 (65%)	0.57
TUMOR RESPONSE
Progression disease	n = 4 (7%)	2 (5%)	2 (10%)
Stable disease	n = 21 (36%)	13 (35%)	8 (40%)
Partial response	n = 29 (50%)	21 (55%)	8 (40%)
Complete response	n = 4 (7%)	2 (5%)	2 (10%)	0.66

The ILCtot frequencies of patients at baseline were distributed into terciles. The results shown for the low (n = 25) and medium (n = 25) terciles were pooled and referred to as ILC low (n = 25 + 25 = 50), and the high tercile was referred to as ILC high (n = 24). ELISpot hTERT response data was available for all 74 patients, however, data for some clinicobiological characteristics are missing for some patients.